A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Ceralasertib (Primary) ; Durvalumab (Primary) ; Infliximab; Mycophenolate mofetil
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms MONETTE
- Sponsors AstraZeneca; AstraZeneca AB
- 27 Jun 2024 Planned End Date changed from 12 Apr 2024 to 30 Jun 2025.
- 18 Oct 2023 Planned End Date changed from 29 Mar 2024 to 12 Apr 2024.
- 18 Oct 2023 Planned primary completion date changed from 29 Mar 2024 to 12 Apr 2024.